Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Jaceosidin/eupatilin; Stillen

Latest Information Update: 07 Oct 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer Dong-A ST
  • Class Cytoprotectives; Phytotherapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Gastric ulcer; Gastritis
  • No development reported Gastro-oesophageal reflux

Most Recent Events

  • 07 Oct 2015 No recent reports of development identified - Preclinical for Gastro-oesophageal reflux in South Korea (PO)
  • 31 Oct 2007 Data presented at the 15th United European Gastroenterology Week (UEGW-2007) added to the adverse events and Peptic Ulcer Disease therapeutic trials sections
  • 01 Aug 2003 Data presented at the Digestive Disease Week - 2003 (DDW-2003) have been added to the Peptic ulcer disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top